Vela Minerals Ltd.

0

Canada & British Columbia Vancouver

700 - West Georgia Street, Suite 2500

velaminerals.com

Looking to explore investment opportunities with VLA?

Contact VLA >

Looking to explore investment opportunities with VLA?

Contact VLA >

Is this your business?
Customize your listing.

CLAIM THIS LISTING

Is this your business?
Customize your listing.

Company Press Releases

IIROC Trading Halt - VLA

VANCOUVER, April 19, 2018 /CNW/ - The following issues have been halted by IIROC: Company: Vela Minerals Ltd. TSX-Venture Symbol: VLA Reason: At the Request of the Company Pending News Halt Time (ET): 09:34 IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada. SOURCE Investment Industry Regulatory Organ...

VALNEVA Delivers Strong 2017 Financial Results and Advances Key R&D Programs

Valneva Delivers Strong 2017 Financial Results and Advances Key R&D Programs The Company expects continued double digit product sales growth in 2018 and to invest further in R&D, notably the Lyme and Chikungunya programs Strong sales and EBITDA performance in 2017 Total revenues and grants of €109.8 million in 2017 (vs. €97.9 million in 2016) Product sales of €92.6 million representing 15% year on year growth EBITDA of €10.8 million in 2017 (vs. €2.8 million in 2016) Improved gross margin of 58% (vs. 56% in 2016) Positive o...

VALNEVA Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15

   Valneva Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15 Phase I study (VLA15-101) primary endpoint met No safety concerns associated with VLA15 in any treatment group Encouraging immunogenicity with VLA15 VLA15 is immunogenic in all doses and formulations tested Good OspA-specific IgG antibody responses against all OspA serotypes Lyon (France), March 19, 2018 - Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused on developing innovative lif...

See All >

Company News

See All >

NEWSLETTER